One HPV Vaccine Shot May Be Enough
A single dose of the vaccine against human papillomavirus, a leading cause of cervical cancer, may be enough to immunize a woman against the disease, a new study has found. Three doses are the current guideline, though research shows that fewer than half of American girls receive the recommended number of doses. More from CNN.com:
“Cervical cancer is a major cause of public health concern, especially in less developed countries where about 85% of cervical cancer occurs,” says study author Mahboobeh Safaeian. “The reason for that is mainly because of lack of screening infrastructure offered.”
Safaeian and her team followed a group of women in Costa Rica who were participating in the National Cancer Institute-funded phase III clinical trial testing the efficacy of Cervarix. About 20% of these women did not complete the three-dose vaccine regimen. Safaeian compared the groups of women who had received one, two and three doses of the vaccine, as well as women who had antibodies from having been naturally infected.
The researchers found that women vaccinated with a single dose of Cervarix, as opposed to the current CDC recommendation of three, had antibodies against HPV that remained stable in their blood after four years. The findings suggest that the common recommendation for three doses may not be necessary to ensure long-lasting antibodies that prevent HPV. Safaeian, a researcher for the National Cancer Institute’s Division of Cancer Epidemiology & Genetics, Infections and Immunoepidemiology, says this could have significant implications for women across the world by simplifying the logistics and costs of vaccinations.
“This vaccine is about $130 a dose … It’s just not feasible in a lot of undeveloped countries,” Safaeian explains.
Image: Girl getting a vaccine, via ShutterstockAdd a Comment